Fluocinolone Acetonide Implant Effective for Refractory Diabetic Macular Edema

Source: Reuters

Most patients with chronic diabetic macular edema (DME) who received a fluocinolone acetonide intravitreal implant did not require additional therapy to lower their intraocular pressure (IOP), according to a registry safety study of the implant (Iluvien, Alimera Sciences), according to a Reuters report.

Earlier treatment with the 0.2 ug/day fluocinolone acetonide (FAc) implant was associated with better outcomes in terms of both IOP and visual acuity, researchers reported online September 21 in the British Journal of Ophthalmology.

Read the full article.

Related Content